article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor. Bringing Daxxify into Offices.

Botox 98
article thumbnail

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

The Pharma Data

are living with spasticity across a variety of neurologic conditions — BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity. Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. million adults in the U.S.

Botox 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

The Pharma Data

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52
article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104
article thumbnail

AbbVie to Present Data From Its Migraine Portfolio at the.

The Pharma Data

–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum.

Botox 52
article thumbnail

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.

Botox 52
article thumbnail

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

pharmaphorum

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 64